Phaseline

Targets › 3CL

3CL: drug programs, companies and trials

3 programs from 3 companies in 7 trials: 4 Phase 3, 2 Phase 2, 1 Phase 4; Infectious disease; next expected readout Jul 2027.

Open in Phaseline: the race on 3CL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ShionogiSecutrelvir
SARS-CoV-2 3CL protease inhibitor
3CLPhase 3COVID-19; SARS-CoV-2Jul 2027
PfizerNirmatrelvir (PF-07321332)
SARS coronavirus 3C-like proteinase inhibitor
3CLPhase 3COVID-19; COVID-19, Long Haul–
Unity Health TorontoPaxlovid
SARS-CoV-2 protease inhibitor
3CL, NSP5Phase 3COVID-19–

Conditions

COVID-19 (5) COVID-19, Long Haul (1) SARS-CoV-2 (1)

Modalities

small molecule (3)

Companies

Pfizer (1) Unity Health Toronto (1) Shionogi (1)

Related targets

NSP5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.